MedCitizens

StartUPDATES: New developments from healthcare startups

Read about new developments from healthcare startups including HealCo, Eikonoklastes, Sidecar Health and more.

Vector illustration - Startup

HealCo’s Health System Without Walls (HSWOW) is healthcare’s tele-hybrid solution. Simply put, we’ve merged traditional brick-and-mortar office visits with telemedicine. Here’s how it works:

  • Telemedicine solves many problems in outpatient care, but there are still visits that require physically going to an office.
  • HSWOW tele-hybrid medical offices host licensed providers who supervise all visits remotely, via video call.
  • The brick-and-mortar office is managed by clinical assistants operating at the top of their license
sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

Click this link to fill out a short survey to get involved. Find out more about HealCo at www.healco.us.


Eikonoklastes, a preclinical biopharmaceutical company developing next-generation tissue factor immunotherapies for triple-negative breast cancer, has closed an oversubscribed seed funding round.  Working with The Ohio State University Corporate Engagement Office and seed investor CincyTech, the company was formed to advance technology discovered and engineered in the lab of Dr. Zhiwei Hu, MD, PhD, and licensed from the Ohio State Innovation Foundation. CincyTech led the financing. To read more, click here.


Encoded Therapeutics, a precision gene therapy company, has raised $135 million in an oversubscribed Series D financing. The company’s lead asset, ETX101, was granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation by the U.S. Food and Drug Administration (FDA) for the treatment of SCN1A+ Dravet Syndrome. GV led the funding round  with participation from Matrix Capital Management, ARCH Venture Partners, Illumina Ventures, RTW Investments, Boxer Capital, Nolan Capital, HBM Genomics, Menlo Ventures, Meritech Capital, Farallon Capital Management, SoftBank Vision Fund 2, and additional unnamed investors. To read more, click here.


Health insurance tech startup Sidecar Health raised $20 million in its most recent funding round. Cathay Innovation led the round, which also included new investors Comcast Ventures, Kauffman Fellows and Anne Wojcicki, co-founder and CEO of 23andMe. Returning investors GreatPoint Ventures and Morpheus Ventures also took part in the round. To read more, click here.

Picture: akindo, Getty Images